[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1187266A1 - 信號轉導途徑的細胞透性肽抑制劑用於治療葡萄膜炎 - Google Patents

信號轉導途徑的細胞透性肽抑制劑用於治療葡萄膜炎

Info

Publication number
HK1187266A1
HK1187266A1 HK14100332.1A HK14100332A HK1187266A1 HK 1187266 A1 HK1187266 A1 HK 1187266A1 HK 14100332 A HK14100332 A HK 14100332A HK 1187266 A1 HK1187266 A1 HK 1187266A1
Authority
HK
Hong Kong
Prior art keywords
jnk
uveitis
cell
treatment
signal transduction
Prior art date
Application number
HK14100332.1A
Other languages
English (en)
Inventor
Jean-Marc Combette
Catherine Deloche
Claire Abadie
Original Assignee
Xigen Inflammation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/006284 external-priority patent/WO2012048721A1/en
Application filed by Xigen Inflammation Ltd filed Critical Xigen Inflammation Ltd
Publication of HK1187266A1 publication Critical patent/HK1187266A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK14100332.1A 2010-10-14 2014-01-10 信號轉導途徑的細胞透性肽抑制劑用於治療葡萄膜炎 HK1187266A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2010/006284 WO2012048721A1 (en) 2010-10-14 2010-10-14 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
EP2011000307 2011-01-25
PCT/EP2011/005172 WO2012048893A1 (en) 2010-10-14 2011-10-14 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases

Publications (1)

Publication Number Publication Date
HK1187266A1 true HK1187266A1 (zh) 2014-04-04

Family

ID=44862926

Family Applications (2)

Application Number Title Priority Date Filing Date
HK14100332.1A HK1187266A1 (zh) 2010-10-14 2014-01-10 信號轉導途徑的細胞透性肽抑制劑用於治療葡萄膜炎
HK15111042.8A HK1210056A1 (zh) 2010-10-14 2015-11-09 信號傳導途徑的細胞透性肽抑制劑用於治療慢性或非慢性炎性眼病的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15111042.8A HK1210056A1 (zh) 2010-10-14 2015-11-09 信號傳導途徑的細胞透性肽抑制劑用於治療慢性或非慢性炎性眼病的用途

Country Status (7)

Country Link
EP (2) EP2902035B1 (zh)
CY (1) CY1120936T1 (zh)
DK (2) DK2627346T3 (zh)
ES (2) ES2575226T3 (zh)
HK (2) HK1187266A1 (zh)
PL (2) PL2902035T3 (zh)
WO (1) WO2012048893A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197098A1 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CN113509541A (zh) * 2014-06-26 2021-10-19 埃克西金炎症有限公司 Jnk信号转导途径的细胞穿透肽抑制剂用于治疗多种疾病的新用途
DE102016111708A1 (de) 2016-06-27 2017-12-28 Heiko Schmidt Gelenkanordnung, vorgefertigte Baugruppe sowie Verfahren zur Herstellung einer vorgefertigten Baugruppe einer Gelenkanordnung
CN108060223A (zh) * 2017-12-29 2018-05-22 北京泱深生物信息技术有限公司 Atf2基因的新应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5747641A (en) 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
CA2146747C (en) 1992-10-09 2006-12-19 Brian A. Naughton Liver reserve cells
CN1208438A (zh) 1995-07-28 1999-02-17 玛丽·柯里癌症治疗中心 转运蛋白及其应用
WO2004054501A2 (en) * 2002-11-18 2004-07-01 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US10045953B2 (en) * 2006-07-06 2018-08-14 Case Western Reserve University Ceramide composition and method of use
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CN102365093A (zh) * 2009-03-30 2012-02-29 参天制药株式会社 用于视网膜疾病的预防剂或治疗剂和使用JNK(c-Jun氨基末端激酶)抑制肽预防或治疗视网膜疾病的方法以及所述肽的用途

Also Published As

Publication number Publication date
DK2902035T3 (en) 2018-09-24
ES2575226T3 (es) 2016-06-27
EP2627346B1 (en) 2016-03-23
DK2627346T3 (en) 2016-06-13
WO2012048893A1 (en) 2012-04-19
EP2627346A1 (en) 2013-08-21
EP2902035A1 (en) 2015-08-05
CY1120936T1 (el) 2019-12-11
PL2902035T3 (pl) 2019-04-30
ES2688030T3 (es) 2018-10-30
HK1210056A1 (zh) 2016-04-15
EP2902035B1 (en) 2018-06-20
PL2627346T3 (pl) 2016-11-30

Similar Documents

Publication Publication Date Title
HK1187266A1 (zh) 信號轉導途徑的細胞透性肽抑制劑用於治療葡萄膜炎
HK1221413A1 (zh) 信號轉導途徑的細胞穿膜肽抑制劑用於治療各種疾病的應用
HK1257444A1 (zh) Cdc7激酶抑制劑以及其用途
IL232699A0 (en) Use of cell-permeable peptide inhibitors of signal transmitters in the jnk pathway to treat dry eye syndrome
HK1202333A1 (zh) 激酶抑制劑的組合及其用途
LT2560947T (lt) Lizino atžvilgiu specifiniai demetilazės-1 inhibitoriai ir jų panaudojimas
HK1179623A1 (zh) 蛋白激酶的抑制劑
GB201016880D0 (en) Phosphodiesterase inhibitors
HK1224225A1 (zh) 信號轉導途徑的細胞滲透肽抑制劑用於治療多種疾病的新用途
ZA201206456B (en) Uses of dgati inhibitors
EP2536709A4 (en) PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE
EP2242501A4 (en) THERAPEUTIC INHIBITORS OF PAI-I FUNCTION AND METHODS OF USE
IL208916A0 (en) Inhibitors of jnk
ZA201300012B (en) Synthesis and use of kinase inhibitors
ZA201300009B (en) Oral formulation of kinase inhibitors
GB0803895D0 (en) Inhibitors of glyoxalase
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
GB0801939D0 (en) Peptide inhibitors of lentiviral replication
GB0908609D0 (en) New use of isoQC inhibitors
GB201017098D0 (en) Carbonic anhydrase inhibitors
GB201002412D0 (en) Carbonic anhydrase inhibitors
GB201003949D0 (en) Inhibitors of protein kinases
GB201019938D0 (en) Determination of therapeutic agents
GB0903651D0 (en) Inhibitors of glyoxalase

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201010